Sign In

Eric Sugalski

CEO & Founder at Archimedic

Eric Sugalski is a seasoned professional with a diverse background in new medical technology, business, and design.

Having started his career as a design engineer, Eric has transitioned through various roles like program management, technical leadership, sales, and general management, culminating in his current position as the CEO of Archimedic.

As the CEO of Archimedic, Eric leverages his expertise to work closely with business development and program management teams, crafting development strategies that meet clients' technical, regulatory, clinical, and commercial goals.

Eric's educational background includes an MBA in Management from the Massachusetts Institute of Technology and a BSME in Mechanical Engineering from the University of Colorado Boulder.

Throughout his career, Eric has been associated with renowned organizations such as Archimedic, University of Pennsylvania, Smithwise, MIT, Insight Product Development, Beamreach Inc, and IDEO.

His experience as a former Lecturer in Bioengineering and Mechanical Engineering highlights his commitment to knowledge sharing and academic contribution in addition to his industry roles.

Highlights

Aug 29 · linkedin

3 Reasons I'm stoked for the HealthTech PHL event on 9/12:

1️⃣ Investors are coming out of the woodwork.

Head count is currently 111, and there are at least a dozen legit medtech and healthtech investors from local VCs and angel groups signed-up.

2️⃣ Great mix of corporates and startups.

Melting pot of backgrounds, roles, technologies, company size/culture but same focus -- development and commercialization of innovative medical products.

3️⃣ New people launching their careers in healthtech.

Fresh grads -- ambitious, smart, and driven to make an impact in healthcare. They'll be there too -- let's welcome them into the local healthtech ecosystem and help them launch their careers.

Want in?

🔗 Sign-up link in the comments.

Aug 27 · linkedin

Who drives strategy in Medtech?

Regulatory or marketing?

Most of the times it's regulatory. And here's what happens:

Focus is on fastest path to market. But then..

  • No clinical data
  • No marketing claims
  • General indication with insufficient reimbursement

Regulatory is a crucial process, but it can't be done in a silo.

It needs to be developed with the right market strategy in-mind.

This is Mini-Series Video 4/6. Interested in the others? See link in comments.

Eric Sugalski
Add to my network

Location

Berwyn, Pennsylvania, United States